United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $501.04, for a total transaction of $2,004,160.00. Following the completion of the transaction, the chief executive officer owned 130 shares of the company’s stock, valued at $65,135.20. This trade represents a 96.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Stock Performance

Shares of UTHR opened at $517.13 on Friday. The business’s fifty day moving average price is $463.63 and its two-hundred day moving average price is $380.56. The firm has a market capitalization of $22.27 billion, a price-to-earnings ratio of 19.60, a PEG ratio of 5.03 and a beta of 0.86. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $518.61.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.89 by $0.27. The business had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $6.39 earnings per share. As a group, research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on UTHR shares. Oppenheimer increased their price objective on shares of United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, September 5th. HC Wainwright increased their price target on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Jefferies Financial Group restated a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a research report on Wednesday, November 19th. Bank of America increased their target price on United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. Finally, Cantor Fitzgerald upped their price target on United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $505.00.

Key Stores Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Director Tommy G. Thompson sold 910 shares but still holds 8,480 shares (~$4.25M), signaling continued insider alignment with shareholders. SEC Filing — Thompson Sale
• Neutral Sentiment: All transactions were disclosed via SEC filings and covered by financial sites, providing transparency; investors should check the filings for whether sales were part of pre-set programs (e.g., 10b5-1) that reduce interpretive weight. SEC Filings
• Negative Sentiment: CEO Martine A. Rothblatt sold a total of 6,000 shares across Dec. 17 and Dec. 19 at ~ $501–$507, leaving her with only 130 shares — a ~94%+ reduction in reported ownership; that sharp drop can be read as a meaningful negative signal to some investors. SEC Filing — Rothblatt Sales
• Negative Sentiment: Additional senior insider sales: CFO and COO transactions reported (CFO ~$1.74M; COO ~$11.17M), increasing the volume and scope of executive selling within days — a likely near-term headwind for sentiment absent an explanatory disclosure. ABN: CEO Sale Coverage ABN: CFO Sale Coverage ABN: COO Sale Coverage

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds have recently modified their holdings of the business. AQR Capital Management LLC grew its position in shares of United Therapeutics by 40.1% in the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after purchasing an additional 364,713 shares during the period. Invesco Ltd. increased its position in shares of United Therapeutics by 90.2% during the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after acquiring an additional 419,588 shares in the last quarter. Darwin Global Management Ltd. acquired a new stake in shares of United Therapeutics during the third quarter worth $317,617,000. Assetmark Inc. raised its holdings in shares of United Therapeutics by 38.1% during the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after acquiring an additional 197,384 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec lifted its position in United Therapeutics by 22.5% in the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 477,757 shares of the biotechnology company’s stock valued at $147,278,000 after acquiring an additional 87,664 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.